---
title: "China Shineway Pharmaceutical Group Limited (2877) Receives a Buy from Guoyuan Securities (HK)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/270254241.md"
description: "In a report released yesterday, from Guoyuan Securities (HK) maintained a Buy rating on China Shineway Pharmaceutical Group Limited, with a price target of HK$10.04.Claim 50% Off TipRanks Premium and Invest with Confidence Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential The analyst consensus on China Shineway Pharmaceutical Group Limited is currently a Hold rating."
datetime: "2025-12-19T05:05:39.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/270254241.md)
  - [en](https://longbridge.com/en/news/270254241.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/270254241.md)
---

# China Shineway Pharmaceutical Group Limited (2877) Receives a Buy from Guoyuan Securities (HK)

In a report released yesterday, from Guoyuan Securities (HK) maintained a Buy rating on China Shineway Pharmaceutical Group Limited, with a price target of HK$10.04.

### Claim 50% Off TipRanks Premium and Invest with Confidence

-   Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
-   Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential

The analyst consensus on China Shineway Pharmaceutical Group Limited is currently a Hold rating.

### Related Stocks

- [02877.HK](https://longbridge.com/en/quote/02877.HK.md)

## Related News & Research

- [CStone Shareholders Approve All AGM Resolutions, Renew Capital Mandates and CEO Equity Awards](https://longbridge.com/en/news/290618548.md)
- [SoftOx Solutions shareholders approve 2025 annual accounts, report](https://longbridge.com/en/news/290674267.md)
- [Samsung Electronics plans 90 trln won share buyback, Yonhap reports](https://longbridge.com/en/news/290629490.md)
- [Sihuan Pharma enrolls first patient in Phase III trial of anaprazole-based H. pylori eradication therapy](https://longbridge.com/en/news/290382040.md)
- [Nordic Halibut completes NOK 24 million Thule Marine, Gulbygget acquisitions](https://longbridge.com/en/news/290586817.md)